Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

532 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-23

Study Completion Date

2028-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

NCT03460275

Non-small Cell Lung Cancer

UNKNOWN PHASE2

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038

Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Gene Mutation Stage III Lung Cancer +1 more

RECRUITING

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683

Carcinoma, Non-Small-Cell Lung

COMPLETED

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951

Lung Cancer

TERMINATED PHASE2

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

NCT06918782

Lung Cancer (NSCLC)

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of this study are to assess the effectiveness and safety of Osimertinib combined with chemotherapy in a real-world setting in patients with locally advanced or metastatic, EGFR mutation-positive NSCLC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Histologically or cytologically documented nonsquamous NSCLC. NSCLC of mixed histology is allowed.
* Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation.
* EGFR sensitive mutation-positive (Ex19del and/or 21 L858R)
* WHO performance status of 0 to 2 at screening with no clinically significant deterioration in the previous 2 weeks.
* Patients who receive Osimertinib plus chemotherapy as first-line treatment based on physician's medical assessment are eligible (For patients who received prior chemotherapy alone/Osimertinib monotherapy/Osimertinib plus chemotherapy as first-line therapy ahead of enrolment, they are diseases progression-free at the time of enrolment and the duration of prior therapy ≤3 months).
* Patients with asymptomatic CNS metastases or patients who have completed definitive therapy, are not on steroids and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids are allowed.
* Prior adjuvant and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiation/chemoradiation with or without regimens including immunotherapy, biologic therapies, investigational agents are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.

Exclusion Criteria

* Spinal cord compression and symptomatic brain metastases
* Past medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD
* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, etc
* Any banned substance in label

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No